Immuron Ltd has released a press release.
Immuron North American revenue surges by 52% in FY19
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- US DoD Reports Results from Travelan Shigellosis Study
- Preliminary Prospectus Supplement filed with SEC
- Trading halt
- Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors
- Immuron sales surge by 66% in the Third Quarter of FY19
Later from Immuron
- Proposed Public Offer of IMRN ADSs
- Immuron Prices Underwritten Public Offering of ADSs
- Underwritten Public Offer
- Immuron Reports Results in SAH Clinical Trial
- Appendix 4E & Annual Report to shareholders
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron